Kevin Gutshall is the Chief CommercialOfficer at Kytopen, where he leads the company’s global growth and commercialstrategy. In 2025, he led the launch and global commercialization of theFlowfect® platform, advancing next-generation cellular engineering solutions for the cell therapy industry.

He is an accomplished commercialand business development executive with proven expertise in portfolio strategy, strategic partnerships, and M&A. He has held senior leadership roles acrosshigh-growth biotechnology companies, consistently driving revenue expansion and long-term value creation.

Prior to joining Kytopen, Kevin served as Chief Business Officer at CellFE, a cellular engineering startup. He previously held the role of Vice President of Strategy and Corporate Development at MaxCyte, where he led corporate growth initiatives, built high-value strategic partnerships, and guided M&A strategy. Earlier in his career, Kevin served as Director of Corporate Development at MilliporeSigma andas Head of Business Development at Sigma-Aldrich, further establishing his reputation as a strategic leader in the Life Sciences.

Kevin’s role will be to provide business and commercial oversight for the Kytopen team into the consortium.